Literature DB >> 288109

Adjuvant interferon treatment of human osteosarcoma.

H Strander, U Adamson, T Aparisi, L A Broström, K Cantell, S Einhorn, K Hall, S Ingimarsson, U Nilsonne, G Söderberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 288109     DOI： 10.1007/978-3-642-81332-0_7

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN： 0080-0015


× No keyword cloud information.
  4 in total

1.  Correlation between lymphocyte-mediated auto-tumor reactivities and clinical course. I. Evaluation of 46 patients with sarcoma.

Authors:  F Vánky; J Willems; A Kreicbergs; T Aparisi; M Andréen; L A Broström; U Nilsonne; E Klein; G Klein
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

2.  Lysis of autologous tumor cells by blood lymphocytes tested at the time of surgery. Correlation with the postsurgical clinical course.

Authors:  F Vánky; E Klein; J Willems; K Böök; T Ivert; A Péterffy; U Nilsonne; A Kreicbergs; T Aparisi
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma.

Authors:  A Rohatiner; J Radford; D Deakin; H Earl; S B Love; O Price; A Wilson; T A Lister
Journal:  Br J Cancer       Date:  2001-07-06       Impact factor: 7.640

Review 4.  Twenty-five years of type I interferon-based treatment: a critical analysis of its therapeutic use.

Authors:  Guido Antonelli; Carolina Scagnolari; Federica Moschella; Enrico Proietti
Journal:  Cytokine Growth Factor Rev       Date:  2014-12-30       Impact factor: 7.638
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.